Capital International Investors Increases Holdings in Teva Pharmaceutical Industries Ltd. $TEVA

Capital International Investors lifted its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 2.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 2,794,784 shares of the company’s stock after purchasing an additional 66,830 shares during the quarter. Capital International Investors’ holdings in Teva Pharmaceutical Industries were worth $87,225,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. Harel Insurance Investments & Financial Services Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 19.2% during the 4th quarter. Harel Insurance Investments & Financial Services Ltd. now owns 44,951,773 shares of the company’s stock valued at $1,402,945,000 after buying an additional 7,255,083 shares in the last quarter. Menora Mivtachim Holdings LTD. raised its holdings in shares of Teva Pharmaceutical Industries by 1.1% during the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 38,920,294 shares of the company’s stock valued at $786,190,000 after buying an additional 427,000 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its holdings in shares of Teva Pharmaceutical Industries by 14.8% during the 4th quarter. Migdal Insurance & Financial Holdings Ltd. now owns 37,402,212 shares of the company’s stock valued at $1,167,323,000 after buying an additional 4,820,000 shares in the last quarter. Norges Bank purchased a new position in shares of Teva Pharmaceutical Industries during the 4th quarter valued at about $1,098,060,000. Finally, Rubric Capital Management LP raised its holdings in shares of Teva Pharmaceutical Industries by 1.8% during the 2nd quarter. Rubric Capital Management LP now owns 26,000,000 shares of the company’s stock valued at $435,760,000 after buying an additional 450,000 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Eliyahu Sharon Kalif sold 153,251 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $35.61, for a total value of $5,457,268.11. Following the completion of the sale, the executive vice president owned 172,184 shares in the company, valued at approximately $6,131,472.24. This trade represents a 47.09% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Amir Weiss sold 10,679 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total value of $384,444.00. Following the completion of the sale, the chief accounting officer owned 20,016 shares of the company’s stock, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 421,470 shares of company stock worth $14,570,945. Insiders own 0.54% of the company’s stock.

Teva Pharmaceutical Industries Price Performance

TEVA opened at $33.24 on Tuesday. The stock’s 50 day simple moving average is $32.89 and its 200 day simple moving average is $31.74. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. Teva Pharmaceutical Industries Ltd. has a 1 year low of $14.99 and a 1 year high of $37.35. The firm has a market cap of $38.22 billion, a price-to-earnings ratio of 24.99, a PEG ratio of 3.49 and a beta of 0.84.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a return on equity of 43.53% and a net margin of 9.01%.The business had revenue of $3.98 billion for the quarter. As a group, analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.36 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on TEVA. Bank of America raised their price objective on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 9th. JPMorgan Chase & Co. raised their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Saturday. Truist Financial raised their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the company a “buy” rating in a report on Thursday, April 30th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Monday, April 20th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $41.78.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.